Physician profile
Nancy E Allegar
NPI 1750387494
$1,204.96
in general payments reported to CMS, 2019-2025
20 companies · $37.89 in 2025
The $37.89 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $956 · 2020: $93.75 · 2021: $37.33 · 2023: $79.99 · 2025: $37.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $79.99 · Food and Beverage: $37.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $79.99 |
| Food and Beverage | $37.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $433.11 | 2019-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $339.10 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Genzyme Corporation | $41.39 | 2019 | |
| Abbvie INC. | $39.84 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $39.66 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $27.71 | 2019 | |
| Jazz Pharmaceuticals INC. | $25.69 | 2019 | |
| Pfizer INC. | $24.66 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $24.26 | 2019 | |
| Glaxosmithkline, LLC. | $14.84 | 2019 | |
| Allergan, INC. | $14.68 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.96 | 2019 | |
| Astellas Pharma US INC | $13.62 | 2019 | |
| Amarin Pharma, INC. | $13.56 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.17 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.92 | 2019 | |
| Genentech USA, INC. | $12.41 | 2019 | |
| Assertio Therapeutics, INC. | $11.24 | 2019 | |
| Phathom Pharmaceuticals, INC. | $9.15 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Allegar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.